These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 8970635)

  • 21. Mycophenolate mofetil/Neoral/steroid vs Neoral/steroid therapy for prophylaxis of acute rejection in renal transplant recipients.
    Carmellini M; Vistoli F; Bellini R; Boggi U; Rindi P; Rizzo G; Mosca F
    Transplant Proc; 1999; 31(1-2):1162-4. PubMed ID: 10083519
    [No Abstract]   [Full Text] [Related]  

  • 22. A pilot study of cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion.
    Thervet E; Morelon E; Ducloux D; Bererhi L; Noël LH; Janin A; Bedrossian J; Puget S; Chalopin JM; Mihatsch M; Legendre C; Kreis H
    Transplant Proc; 2000 Dec; 32(8):2778. PubMed ID: 11134800
    [No Abstract]   [Full Text] [Related]  

  • 23. Mycophenolate mofetil (Cellcept) in renal transplantation: the European experience. The European Mycophenolate Mofetil Co-operative Study Group.
    Carl S; Wiesel M
    Transplant Proc; 1997 Nov; 29(7):2932-5. PubMed ID: 9365619
    [No Abstract]   [Full Text] [Related]  

  • 24. Late conversion to mycophenolate mofetil for chronic deterioration of renal allograft function.
    Fritsche L; Sperschneider H; Budde K; Giessing M; Türk H; Böhler T; Schröder K; Stein G; Neumayer HH
    Transplant Proc; 1998 Aug; 30(5):2229. PubMed ID: 9723451
    [No Abstract]   [Full Text] [Related]  

  • 25. The early impact of mycophenolate mofetil in combination with steroids and cyclosporine Neoral after renal transplantation: a six-month analysis.
    Cubas A; Herrero JC; Morales E; Carreño A; Dominguez-Gil B; Cirujeda A; Praga M; Ortuño T; Hernandez E; Delgado M; Andres A; Morales JM
    Transplant Proc; 1999 Sep; 31(6):2265-6. PubMed ID: 10500570
    [No Abstract]   [Full Text] [Related]  

  • 26. Lymphocyte subsets in renal transplant recipients treated with mycophenolate mofetil.
    François M; Büchler M; Halimi JM; Al-Najjar A; Valentin JF; Thibault G; Lebranchu Y
    Transplant Proc; 2000 Dec; 32(8):2781-2. PubMed ID: 11134803
    [No Abstract]   [Full Text] [Related]  

  • 27. Mycophenolate mofetil in the prevention of rejection after kidney transplantation.
    Kiehl MG
    Transplantation; 2000 Apr; 69(8):1753-4. PubMed ID: 10836400
    [No Abstract]   [Full Text] [Related]  

  • 28. Postmarketing evaluation of mycophenolate mofetil-based triple therapy immunosuppression compared with a conventional azathioprine-based regimen reveals enhanced efficacy and early pharmacoeconomic benefit after renal transplantation.
    Wüthrich RP; Weinreich T; Schwarzkopf AK; Candinas D; Binswanger U
    Transplant Proc; 1998 Dec; 30(8):4096-7. PubMed ID: 9865310
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of the safety and efficacy of mycophenolate mofetil, prednisolone and cyclosporine and conventional cyclosporine and prednisolone in kidney transplantation.
    Kim HC; Park SB; Kim HT; Cho WH; Park CH
    Transplant Proc; 2000 Nov; 32(7):1751-2. PubMed ID: 11119919
    [No Abstract]   [Full Text] [Related]  

  • 30. A prospective randomised study of CSA monotherapy versus CSA plus mycophenolate mofetil in cadaveric renal transplant recipients.
    Sells RA; Bakran A; Brown MW; Grinyo J; Hammad A; Hyatt D; Owens G
    Transplant Proc; 1998 Dec; 30(8):4098. PubMed ID: 9865311
    [No Abstract]   [Full Text] [Related]  

  • 31. A one-center experience with a short course of mycophenolic acid.
    Stephan A; Barbari A; Kamel G; Aoun S; Masri MA
    Transplant Proc; 1999 Dec; 31(8):3289-90. PubMed ID: 10616479
    [No Abstract]   [Full Text] [Related]  

  • 32. [Mycophenolate mofetil].
    Abramowicz D; Broeders N; Wissing M; Sternon J
    Rev Med Brux; 1998 Jun; 19(3):139-43. PubMed ID: 9697397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid steroid withdrawal versus standard steroid therapy in patients treated with basiliximab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantation.
    Vincenti F; Monaco A; Grinyo J; Kinkhabwala M; Neylan J; Roza A; Somberg K
    Transplant Proc; 2001; 33(1-2):1011-2. PubMed ID: 11267168
    [No Abstract]   [Full Text] [Related]  

  • 34. The evolving role of mycophenolate mofetil in renal transplantation.
    Warrens AN
    QJM; 2000 Jan; 93(1):15-20. PubMed ID: 10623777
    [No Abstract]   [Full Text] [Related]  

  • 35. Mycophenolate Mofetil Study.
    Baltzan M; Shoker A; Baltzan R
    Transplantation; 1997 Jan; 63(1):173-4. PubMed ID: 9000687
    [No Abstract]   [Full Text] [Related]  

  • 36. Mycophenolate mofetil monotherapy: an example of a safe nephrotoxicity/atherogenicity-free immunosuppressive maintenance regimen in a selected group of kidney-transplanted patients.
    Keunecke C; Rothenpieler U; Zanker B; Schneeberger H; Illner WD; Theodorakis J; Stangl M; Land W
    Transplant Proc; 2000 Feb; 32(1A Suppl):6S-8S. PubMed ID: 10686310
    [No Abstract]   [Full Text] [Related]  

  • 37. Triple therapy with mycophenolate mofetil versus azathioprine.
    Muñiz ML; Amenabar J; Gómez-Ullate P; Urbizu J; Lampreabe I
    Transplant Proc; 1999; 31(1-2):1144-6. PubMed ID: 10083512
    [No Abstract]   [Full Text] [Related]  

  • 38. Mycophenolate mofetil slows the decline of renal function in patients with biopsy-proven chronic rejection: a collaborative pilot study.
    Campistol JM; Mazuecos A; Segura J; Osuna A; Herrero JC; Andres A; Oppenheimer F; Gomez de la Camara A; Martinez MA; Morales JM
    Transplant Proc; 1999 Sep; 31(6):2267-9. PubMed ID: 10500571
    [No Abstract]   [Full Text] [Related]  

  • 39. [Immunosuppressive drug monitoring of cyclosporine, tacrolimus, and mycophenolate mofetil in renal transplantation].
    Uchida K
    Nihon Jinzo Gakkai Shi; 2005; 47(4):423-9. PubMed ID: 15971884
    [No Abstract]   [Full Text] [Related]  

  • 40. Mycophenolate mofetil eliminates the rationale for antilymphocyte induction therapy in nonhaploidentical living-donor kidney transplants.
    Shaffer D; Madras PN; Conway P; Davis C; Simpson MA; Monaco AP
    Transplant Proc; 1997; 29(1-2):342-3. PubMed ID: 9123031
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.